Video: Developing the drug LB-100 to inhibit PP2A
December 21, 2023
Video: Update on Progress with Proprietary LB-100 Compound
March 20, 2024
Matheus Dos Santos Dias, a researcher at the Netherlands Cancer Institute. He is working on a Lixte drug.
Pasadena-based pharmaceutical company Lixte Biotechnology Holdings Inc.’s new chief executive is also charting a new course for the company and its cancer treatment drug.
Bas van der Baan, a veteran biotech executive, took over as chief executive last fall as the company founder and longtime chief executive, John Kovach, retired and then passed away at age 87. Baan has taken the helm as the company is embarking on clinical trials of its main drug candidate.
